The biopharmaceuticals giant and drugmaker are combining to create a leader across immunology, neuroscience, eye care and other medical fields.
Abbvie has agreed to buy Allergan in a $63 billion cash-and-stock deal. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share that they hold, totaling $188.24 per Allergan share. The offer represents a 45% premium to the closing price of Allergan's shares on June 24, 2019.
Abbvie has agreed to buy Allergan in a $63 billion cash-and-stock deal. Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share that they hold, totaling $188.24 per Allergan share. The offer represents a 45% premium to the closing price of Allergan's shares on June 24, 2019.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AbbVie Nears Deal to Buy Allergan for More Than $60 BillionAbbVie is nearing a deal to buy Allergan for more than $60 billion, as the two big drug makers bet a combination will deliver new sources of growth they have struggled to find on their own.
Read more »
AbbVie Nears Deal to Buy Allergan for More Than $60 BillionAbbVie is nearing a deal to buy Allergan for more than $60 billion, as the two big drug makers bet a combination will deliver new sources of growth they have struggled to find on their own.
Read more »
Eldorado Resorts to buy Caesars Entertainment for about $8.5 billionEldorado Resorts Inc has agreed to buy Caesars Entertainment Corp for about $8.5...
Read more »
Eldorado Resorts takes on bigger rivals with $8.5 billion Caesars buyU.S. casino operator Eldorado Resorts Inc has agreed to buy rival Caesars Entert...
Read more »
Caesars' stock soars after Eldorado buyout deal values casino operator at about $8.6 billionShares of Caesars Entertainment Corp. soared 16% toward an 11-month high in premarket trading Monday, after the casino operator agreed to be bought out by...
Read more »
Circor rejects Crane's buyout deal valued at $1.7 billionCircor International Inc. said Monday it has rejected the unsolicited buyout bid from Crane Co. given that it 'substantially undervalues' the flow...
Read more »